Artikelen

This reading list we received from Drs entirely disinterested. E. Valstar, (Orthomolecular) doctor / biologist. We provide this list are unchanged for publication. .

Scroll down for list.

Valstar wrote the book Nutritional intervention in cancer, a signal to the conventional oncology. See description on page, etc. ISBN cancer rates. We want to mention that we have no business or substantive ties with Engelbert Valstar, but this book and lists seem to us so interesting that we want to change places. Questions / comments can be sent to the editor: redactie@kanker-actueel.nl We will keep your questions / comments to be forwarded Valstar. Also on this list and further information on this page is of course our disclaimer applies.

More detailed descriptions and other studies see and nutrition research. And we try to at least the abstract and the results of the Phase III trials and pivotal Phase II studies in the literature list and nutrition research. or current mainstream research to publish or not fitted comments.

For regular treatments in general because the only randomized study possible side effects. Moreover, a randomized study of conventional treatments often never implemented. This assertion of Valstar based on relevant literature is in NTvG (see NTvG 136: 709-710, 1992) by the respective oncologists not contradicted.
See also Nutritional Oncology, Heber D. et al ISBN 0-12-335960-0, the book was edited by Harvard and by the Memorial Sloan Kettering Institute! ).
(Editors note: See extensive bibliography in the book of Valstar Nutritional intervention in cancer, a signal to the conventional oncology and now as published on this site)..

To this list are Hans Houtsmuller, Ed Woerlee Johan Bolhuis and important contributions.

Bibliography of studies cancer and nutrition / supplementation. Studies: 1 t / m 100

Bibliography randomized (and in some cases also double-blind) trials, in which a possible therapeutic effect of one or more parameters or other complementary feeding method is evaluated.

For regular treatments in general because the only randomized study possible side effects. Moreover, a randomized study of conventional treatments often never implemented. This assertion of Valstar based on relevant literature is in NTvG (see NTvG 136: 709-710, 1992) by the respective oncologists not contradicted. References 3, 4 and 24 are "duplicates", 5 and 8 and also that fact that this was also the references 16 and 18. Reference 21 is called a single-blind study, in terms of quality comparable with a randomized trial. Also references 22, 23, 24, 26, 66 and 67 are "duplicates". Ditto for the references 27, 28 and 29. For the treatment of small cell lung cancer, there are two studies with thymus, which showed a better survival (36 and 37, but see also 33).

References 41 and 42 are additive. References 38 and 50 are also each other.

See the 13 studies with 5-FU and leucovorin for metastatic cancer.

Studies 64 and 69 are both on the use of PSK in breast cancer. References 7 and 142 on both Zhuling act as an adjunct to bladder cancer.

See also Nutritional Oncology, Heber D. et al ISBN 0-12-335960-0, the book was edited by Harvard and by the Memorial Sloan Kettering Institute!

To this list are Hans Houtsmuller, Ed Woerlee Johan Bolhuis and important contributions.

1) Lamm DL et al, J Urology 151 :21-26, 1994, for bladder cancer shows a significant beneficial effect of A, C, E, B6 and zinc. The study was also double. The lower risk of recurrence within five years means in terms KWF (Koningin Wilhelmina Fonds) a better chance of recovery.

2) Krisnamurthi S et al, Radiology 99: 409-415, 1971. 1) Krisnamurthi S et al, Radiology 99: 409-415, 1971. Vitamin K3 cheek cancer doubles the chance of recovery.

3) Toriso M et al, Cancer Immunol Immunother 1990, 31: 261-8. In this double-blind study reduces the PSK mushroom Coriolus Versicolor fraction of mortality in cancer patients (Dukes' stage C) significantly by 15%.

4) T Mitomi et al, Dis Colon Rectum 1992, 35 (2): 123-30. This research is actually a replica of reference 3, which also reduces the aforementioned PSK group the mortality of colorectal cancer patients

5) Aso Y et al, Eur Urol 1995, 27: 104-109. This is a significant therapeutic effect in bladder cancer of a lactic acid bacteria demonstrated. This study was also double. The therapeutic effect here contained a significantly longer disease-free period if the lactic acid bacteria were used.

6) S Heys et al, Int J Oncol 1998, 12: 221-5. In this randomized study showed the amino acid L-arginine in breast cancer response to chemotherapy significantly improve chances.

7) DA Yang et al, Chung-Hua-Wai-Ko-Tsa-Chih 1994, 32 (7) :433-4. This study shows the effect of bladder cancer in the Chinese herb Zhuling be as good as that of the standard BCG treatment (reduces risk of recurrence over time).

8) Aso Y and Akazan; Urol Int 1992, 49 (3): 125-9. Reference 5 (double) is an actual repetition of this small randomized study, this small study is also a significant therapeutic effect.

9) G Manolakis et al, Deutsche Zeitschrift fur Onkologie 27: 124-129, 1995. This study shows primrose oil the lives of patients with metastatic colorectal cancer by about one year longer.

10) Gogos CA et al, Cancer 1998, 82 (2): 395-402. Omega-3 fatty acids plus vitamin E in this randomized study extend the life of terminal cancer patients.

11) Sopotsinskaia EB et al, Vopr Onkol 1992, 38 (5) :592-9. Calorie restriction was in this randomized study to slow the progression of breast cancer.

12) Lissoni P et al, Oncology 1996, 53 (1) :43-46. In this randomized study showed melatonin the lives of patients with an astrocytoma grade 4 to extend.

13) Lissoni P et al, J Pineal Res 1996, 21 (4) :239-42. In this randomized study showed the melatonin group after 31 months significantly fewer relapses to know.

14) Pastorino U et al, J Clin Oncol 1993 11 (7) :1216-22. Retinol in very high doses reduces the risk of recurrence in lung cancer patients significantly.

15) Meyskens FL et al, Leuk Res 1995: 19 (9): 605-612. Vitamin A inhibits progression of chronic myeloid leukemia.

16) Lissoni P et al, Oncology 1992, 49 (5) :336-9. In patients with non-small-cell lungcancer there with cisplatin plus melatonin significantly more people alive after one year than with cisplatin alone.

17) Lissoni P et al, Cancer 1994, 73 (3): 699-701. Melatonin Plus "supportive care" indicated in patients with brain metastases from solid tumors after one year a significantly better survival than if only "supportive care" was used.

18) Lissoni P et al, J Pineal Res 1997, 23 (1): 15-9. Etoposide plus cisplatin plus melatonin indicated in patients with non-small-cell-lung cancer-a significantly better survival at 1 year than when only two were given chemotherapy. Since the parameters in this study cisplatin versus cisplatin and melatonin are present, this study actually a "duplicate" of reference 16.

19) D Thornes et al, Eur J Surg Oncol 1989, 15 (5) :431-5. Coumarin adjuvant reduces the risk of recurrence in patients operated due to a substantial melanoma, which was a randomized trial.

20) Ripamonti C et al, Cancer, 82 (10) 1938-1945. Zinc promotes recovery after chemotherapy taste significantly better than placebo.

21) Kucuk O et al, Cancer Epidemiol Biomarkers Prev 10: 861-8, 2001. This study shows conclusively that lycopene is capable of prostate cancers in growth to slow.

22) H. Nakazato et al, Gan To Kagaku Ryoho 1989, 16 (8Pt1): 2563-2576. PSK (Coriolus Versicolor derived from the fungus) increases in gastric cancer patients disease-free interval and reduces mortality at a period of over two years.

23) Kondo T et al Biotherapy 1991, 3 (4): 287-95. Again in gastric cancer patients found a beneficial effect of PSK, although this was significant only in a subset (it was a lower mortality). It was a relatively small study, which will always differ significantly slower.

24) H. Nakazato et al, Gan To Kagaku Ryoho 1986, 13 (2) :308-18. Patients with gastric cancer in stage 3 had in this randomized study of PSK a better prognosis, as were patients with colon cancer Dukes' stage C.

25) Nishiwaki Y et al; Gan To Kagaku Ryoho 1990, 17 (1): 131-6. Lung cancer patients in stage 3 have a better prognosis with adjuvant PSK, for stage 4 lung cancer patients was not found.

26) Ichihashi H et al; Gan To Kagaku Ryoho 14 (9) :2758-66. Here is the group of gastric cancer patients with PSK is better off, although the difference is not significant.
A preliminary meta-analysis of the references 22,23,24 and 26 allow an unambiguous
beneficial effect of PSK in gastric cancer seen.

27) Akimoto M et al; Gan To Kagaku Ryoho 15 (4 pt 2-1): 827-833, 1988. Lentinan
(Shiitake) improves the prognosis of gastric cancer study randomized patients.

28) Taguchi T, detects Prev Cancer (Suppl) :333-January 49, 1987: This study is no 29 and 27 with no comparable, though, that no 29 gastric cancer patients and patients with colorectal carcinomas were combined.

29) Wakui A et al; Gan To Kagaku Ryoho 13 (4 Pt 1): 1050-59, 1986.

30) Trutwin H. Physician and alternative 1989, 3: 11-12. In this randomized study showed a thymuspreparaat the lives of patients with breast cancer reported about 1 years.

31) Azizi E et al, Arzneimittelforschung 1984, 34 (9): 1043-7. Thymostimuline randomized study in adjuvant improves the survival of melanoma patients.

32) Mustacchi G et al, Anticancer Research 1994, 5-FU plus leucovorin with or without thymostimuline randomized study had the following results: with thymostimuline were significantly more regressions and significantly fewer side effects.

33) OJ Chrétien et al, Cancer Treatment Rep 1978; 2 (11): 1787-90; thymosin in double-blind study shows the results of chemotherapy in small cell undifferentiated lung cancer improve, at low initial T-cell levels.

34) Federico M et al, Am J Clin Oncol 1995: 18 (1): 8-14. In patients with non-Hodgkin's lymphoma of intermediate or high malignancy, showed significantly more regression thymostimuline give the survival at 4 years was in contrast to what the authors say in the patients treated with thymostimuline better.

35) The Serdio JL et al, Acta Otorrinologica Esp 1997; 48 (6): 487-92, 2 groups of 18 patients with head and neck cancer receiving chemotherapy plus radiation, and whether or not thymostimuline, the thymostimulinegroep did not significantly better, given the short follow-up and the low rate of recurrence (2 with distant metastases in thymostimuline and 4 in the control group) is given the small size of the groups, any conclusion impossible.

36) P Macchiarini et al, Anticancer Research 1989, 9 (1): 193-6: thymostimuline with improved survival in randomized studies in patients with small cell undifferentiated lung carcinoma.

37) Cohen MH et al, JAMA 1979, 241 (17): 1813-5, are the same as the authors under 36, see also 33.

38) Byars D, Blackard C, Urology 10: 556, 1977, vitamin B6 reduces the risk of recurrence according to randomized study of bladder cancer significantly.

39) Lissoni P et al, Br J Cancer 1994, 69: 196-9; melatonin increases in this randomized study in cancer risk significantly the regression by interleukin 2.

40) Iaffaioli RH et al: Thymus 1988-1989, 12 (2): 69-75; thymostimuline reduces randomized study infections and bone marrow toxicity in chemotherapy for breast cancer significantly.

41) Okawa T et al, Cancer 1993: 72: 1949-54; Lactic acid bacteria improve randomized study of the relapse-free survival and survival in cases of cervical cancer significantly.

42) Okawa T et al, Cancer 1989, 64: 1769-76: lactic acid bacteria to improve the outcome in randomized studies of radiotherapy in cervixcarcinoompatiënten.

43) van der Merwe et al; Prostagl Leukot Essent Fatty Acids 1990, 40 (3): 199-202: evening primrose oil seems to be in double-blind study is not effective in primary liver carcinomas, a closer analysis shows however that depicts flower oil group still demonstrated live longer.

44) Ogoshi K et al, Am J Clin Oncol 1995, 18 :216-222, PSK improved in this randomized study nonsignificant survival in esophageal cancer (P 0.1 to 0.2 depending on which button was used, this represents that 80 to 90 percent certain that the PSK improves survival in esophageal cancer patients). Multivariate analysis showed exposure to PSK, however, have a better survival for the subgroup that both radiotherapy and chemotherapy had.

45) Mitomi T et al; Gan To Kagaku Ryoho 1986, 13 (8): 2532-7; PSK improved in this randomized study of survival in gastric cancer patients.

46) Hancke AB, Prog Clin Biol Res 1988, 259: 307-320. Vitamin C appears in a randomized trial of radiotherapy to improve results and reduce side effects.

47) From Zandwijk N et al, J Natl Cancer Institute 2000 June 21, 92 (12): 977-86, Vitamin A, followed by fluimicil ineffective as a form of secondary prevention in patients previously treated for throat or lung cancer. The lung cancer group, together with reference 14 jointly analyzed.

48) Show Doro JH et al, J Clin Oncology 1990, 8 (3), 491-501. Leucovorin calcium potentiates 5-FU and thus prolongs life in patients with metastatic colorectal cancers.

49) Cg Moertel et al, N Engl J Med 1985, 312: 137-41; Vitamin C prolongs life in patients with metastatic cancer not, this research has been analyzed by me and found wanting (see Moerman Report, Chapter 5); The conclusion is that the study because of poor planning does not allow conclusions.

50) DW Newling et al, Eur Urol 1995, 27 (2): 110-6; Vitamin B6 reduces the risk of recurrence of bladder cancer is not.

51) Lissoni P et al, Oncology Reports 1995, 2: 871-873; Melatonin increases in "hormone refractory" patients randomized study the possibility of a partial response by Nolvadex.

Here are a few studies (12) with 5-FU and leucovorin in patients with metastatic colorectal cancer, after preliminary analysis which shows that the response probability of leucovorin 5-FU increases. See also reference 48.Vooralsnog no significant additional life extension by leucovorin detectable.

52) Petrelli N et al, J Clin Oncol 1987; 5: 1559-1565.
53) Valone FH et al, J Clin Oncol 1989, 7: 1427-1436.
54) Ehrlichman C et al, J Clin Oncol 1988; 6: 469-75.
55) Petrelli N et al, J Clin Oncol 1989, 7: 1419-1426.
56) O'Connell MJ, Cancer 1989, 63: 1026-1030.
57) Nobile M et al, Adv Exp Med Biol 1988; 244: 213-18.
58) R LaBianca et al, Ann Oncol 1991; 2: 673-9.
59) Dicontanzo F et al, Ann Oncol 1992; 3: 371-6.
60) Stemke B et al, Semin Oncol 1992, 19 (Suppl 3): 141-7.
61) Martoni A et al, Anticancer Res 1992, 12: 607-12.
62) Bobbio-Palacini E et al, J Chemother 1993, 5 :52-5.
63) Leichman CG et al, J Clin Oncol 1995, 13: 1303-1311.

64) Toi M et al, Cancer 1992, 70: 2475-83, PSK, the survival of patients with hormone refractory breast cancer improve.

65) Go P and CH Chung, J Int Med Res 1989, 17: 141-149; PSK improves randomized trial in patients with nasopharynxcarcinoom both recurrence-free survival and survival significantly sec.

66) Niitomi M et al, Jap J Surgery 1988, 18 :681-686, PSK provides a significantly better survival in gastric cancer, according to this large randomized study.

67) H. Nakazato et al, Lancet 1994, 343: 1122-1126, PSK improves survival in gastric cancer.

68) Nagao T et al; Tokai J Exp Clin Med 1981; 6: 141-6; PSK prolongs remission duration in acute leukemia.

69) Iino Y et al, Anticancer Res 1995, 15: 2907-12; Significant improvement in survival in patients with breast cancer by PSK

70) Nio Y et al, Biotherapy 1992, 4:117-28; significant immune stimulation by PSK in patients with gastric or colon cancer.

71) A. Hara et al, Gan To Kagaku Ryoho 1998, 25: 1173-7, 5-FU with leucovorin improves survival in the adjuvantsituatie Dukes B + C patients with more than 5-FU adjuvant therapy alone. When has also given levamisole, leucovorin does not seem more important (Ann Oncol 2000, 11: 547-52)

72) Ogoshi K et al, American J Clin Oncol 1995, 13: 363-69; PSK improves survival in patients with esophageal cancer.

73) Xu GZ et al, Int J Radiation, Oncology, Biology, Physics 1989, 16: 297-300; The herb "destagnation" improves the outcome of radiotherapy in patients with advanced nasopharynxcarcinoom significant.

74) ZQ Wang, Chung-Kuo Chung Hsi i Chieh Ho Tsa Chih 1992, 12: 609-10, 581; an IV administered extract of Brucea javanica prolongs the median survival of patients irradiated for brain metastases of lung, significant.

75) I. Adachi et al, Gan To Kagaku Ryoho (= Japanese J of Cancer and Chemotherapy) 1989, 16: 1538-1543, significantly improves survival-to Juzentaiho of breast cancer patients with chemotherapy and hormonal therapy.

76) Zhou A et al; Chung Hsi i Chieh Ho Tsa Chih (Chinese J Modern Developments in Traditional Medicine 1990, 10: 343-4, 324.Gemodificeerde xiao-jin pills improve survival in patients with stage 4 stomach cancer significantly.

77) XY Liu and Ang NQ; Chung Hsi i Chieh Ho Tsa Chih (Chinese J Modern Developments in Traditional Medicine) 1990, 10: 720-2, 708. Jin Qui Shen Qi extract (Liu Wei Di Huang = extract) improves in patients with small cell lung cancer response to chemotherapy, the side effects of chemotherapy and improves median survival (all of course significant).

78) Lenartz D et al, Anticancer Research 20: 2073-76, 2000, Mistletoe extract prolongs survival in patients with an astrocytoma grade 3 and / or 4 significantly.

79) B. Ost, Deutsche Zeits. Onkol. 21: 102-104, 1989. Factor AF2 reduces randomized study the risk of recurrence in breast cancer.

80) OR Long, Beilage zur Zeitschrift ONKOLOGIE 10: 40-43, 1987: Factor AF-2 during chemotherapy for breast cancer reduces vomiting significantly.

81) M Kindler, Z. (Fur) Onkologie 29: 7-10, randomized trial in breast cancer patients reduces factor AF-2 during chemotherapy leukopenia and vomiting significantly.

82) Papadopoulos I, Wand H, Beilage zur Zeitschrift ONKOLOGIE, Band 12: 26-31; factor AF-2 reduces in this randomized study the effects of experimental chemotherapy in prostate cancer patients.

83) Yamamura Y et al, Cancer Research 1983, 43: 5575-9; Nocardia improves the survival according to randomized studies in lung cancer patients with pleural effusion.

84) Wolmark N et al, J Clin Oncol 1993, 11: 1879-1887, folic acid improves survival as an adjuvant in the treatment of cancer patients with 5-FU.

85) O'Connell MJ et al, J Clin Oncol 15: 246-50, 1997, this study is comparable to no 84.

86) O'Connell MJ et al, J Clin Oncol 15: 246-50, 1997, this study is comparable to no 85.

87) Lissoni P, Nat Immun 1998, 16 (1): 27-33; aloe inhibits tumor growth and improves survival in randomized study (the patients in this study were all also melatonin).

88) Silverman JE et al, J Oral Med 1983, 38:14-6; Zinc accelerated in this randomized double-blind study taste recovery after radiotherapy for head / neck cancer.

89) K. Okamura et al, Cancer 1986, 58:865-872; Schizophyllan randomized study improves survival of patients with cervical cancer.

90) ZY Tang et al, Med Oncol Tumor & Pharmacoth 1991, 8 :23-28; Coley method with improved survival in randomized studies in patients with inoperable primary liver cancer.

91) Kempin S et al, Proc Am Soc Clin Oncol 1983, 24: 56; Coley treatment according to the principle improves survival in patients with non-Hodgkin's lymphoma.

92) s Koyama et al, Cancer Immunol Immunother 1986, 22: 148-54; Nocardia improves survival in gastric cancer.

93) Ohno R et al, Cancer 1986, 57: 1483-8; Nocardia extract improves survival 5 years in patients with myeloid leukemia.

94) Yasumoto K, Yamamura Y, Biomed Pharmacother 1984, 38: 48-54; Nocardia extract improves prognosis lung cancer patients.

95) Cascinu S et al, J Clin Oncol 1995, 13 (1): 26-32; Glutathione improves the response probability of cisplatin in patients with gastric cancer and reduces side effects detectable.

96) Ohno R et al, Cancer Immunol Immunother 1984, 18: 149-150. In this study of PSK a longer survival in patients with non-lymphocytic leukemia seen.

97) Sturgeon MK et al, Eur J Cancer 37: 9-11, 23-31, 2001: Mistletoe is not effective in head and neck cancer, doctors give the anthroposophic mistletoe just to immunogenic tumors and that includes not these tumors, which is also only the fourth study in this list, which will not benefit from an alternative approach is found.

98) Schmidinger M et al, Wien Klin Wochenschr 112: 617-23, glutathione reduces the side effects of cisplatin in patients with throat cancer or small cell lung cancer, the regression risk and survival were the glutathiongroep better, but the latter were by the small numbers are not statistically hard to do.

99) Grotz KA et al, PMID: 11178853 UI: No Cit. Assigned ID, Title: Prophylaxis of radiogenic sialadenitis and mucositis by coumarin / troxerutin in patients with head and neck cancer - a prospective, randomized, placebo-controlled, double-blind study, in this study with coumarin plus troxerutin proven to reduce side effects of radiation given , in patients who, because of throat cancer radiation therapy. Moreover, the result of better treatment.

100) The Mary D et al, Treatment of Tumors 78: 374-6, 1992; glutathione reduces randomized study the effects of radiotherapy in patients with endometrial cancer.